A new voice same nonsense
There are days when we wonder whether the folks at MannKind (NASDAQ:MNKD) are secretly reaching out to all these people who continually write about how great the stock is going to be. Honestly we can just see clandestine meetings or secret dispatches being exchanged between MannKind Ken, Gomer and Robbie. We can just a imagine MannKind reaching out to these people and saying something like “Hey we’re going to be in Chicago at the Marriott on Michigan avenue room 329, stop by when you get the chance.”
We mention this as today we have a new voice in the MannKind zealot arena, say hello to Joshua Rodriguez who according to his bio;
“Hey everyone, I’m Joshua Rodriguez. I’m the founder of CNA Finance as well as several other sites. If you’d like to connect with me, follow me on Google+ or Twitter! I’d love to see ya there. Also, if you’re looking for top quality content for your blog, please visit my new website,JRodWrites.com!”
This bio is followed by the following disclaimer;
“The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from CNAFinance). The author has no business relationship with any company whose stock is mentioned in this article.”
Ok so here we have a guy who at least on the surface has no vested interest in MannKind, or at least he won’t have a position for another 72 hours, which for anyone who’s followed shares of MannKind understands is a lifetime. It also appears that JRod, which makes us wonder whether he’s related to ARod or J-lo but we digress, whether Rod has any knowledge of this wacky world, is just another shameless pump and dumper or is just stupid.
According to the big Rod;
“However, it’s important to remember that MannKind isn’t the only company with their hands in this basket of golden eggs; Sanofi is playing a huge role as well. While Afrezza is created and produced by MannKind, it is licensed to Sanofi with regard to promotion and distribution. This means that as Afrezza becomes the major hit investors, analysts, and other experts expect it to become, gains from Afrezza could offset losses from generic versions of Lantus for Sanofi; leading to maintained revenue and profits!”
It’s amazing how many misstatements the big Rod can get into a paragraph that contains three sentences and 84 words. Yes Sanofi (NYSE:SNY) is playing a major role which based on their track record for diabetes products not named Lantus is not necessarily a good thing. Yet adding that everyone expects Afrezza to become a major hit is a real dozy. About the only people expecting this are the ones who are using the Exubera bong to deliver a good high or the folks in France who’ve had one Makers Mark too many. But the true whopper is this delusion that Afrezza will generate lots of revenue and profits. This reminds Diabetic Investor of the scene in Monty Python and the Holy Grail where the Black Knight is getting his arms and legs hacked off all the time saying it’s only a flesh wound.
But wait it gets better as the big Rod concludes by stating;
“Moving forward, I’m expecting to see great things out of both companies. However, I do have to say that there is much more potential for growth in MNKD than in SNY in my opinion. While Afrezza will positively affect Sanofi, Lantus will definitely see some losses over the next year or two. However, MannKind has nothing to lose and all to gain; so we should see big long term gains from the stock.”
Listen anytime anyone uses the phrase “long term gains” associated with MannKind in any way whatsoever is in serious need of help. Honestly we thought Ken, Gomer and Robbie were a little off but the big Rod has truly left the reservation.
Let’s just say that at this point Diabetic Investor must respectfully disagree with these idiots and their off the wall reasons for why MannKind’s stock is a good investment. Yes it makes good copy but my goodness one just might think that even these morons would know when it’s time to say uncle.
